COL1A2 and neoplasm: TPL-mediated disruption of cell-specific SEs to downregulate gene expression (MYC, BRD4, RNA Pol II, COL1A2, etc.), as elucidated here, implies its therapeutic relevance in targeting both stromal and tumor compartments of PDAC.